Literature DB >> 3486938

Tolerance to rat monoclonal antibodies. Implications for serotherapy.

R J Benjamin, S P Cobbold, M R Clark, H Waldmann.   

Abstract

The antiglobulin response is a major complication of mAb therapy. It has been suggested that, in clinical practice, this might be avoided by using human or chimeric mAbs, or by prior induction of tolerance to the therapeutic mAb. In this study, we show that it is possible to induce tolerance in mice to the constant regions of rat IgG2b mAbs by both classical deaggregation methods and by anti-L3T4 mAb therapy. Mice tolerant to IgG2b constant region determinants failed to make an antiglobulin response when immunized with a number of mAbs of the same isotype that had no binding specificity for mouse cells, but produced vigorous antiidiotypic responses to cell-binding mAbs. Binding of antibodies to hemopoietic cells rends their idiotypic determinants major immunogens even in the presence of tolerance to constant region epitopes. These findings suggest that the use of human or chimeric mAbs will not be sufficient to eliminate the antiglobulin response, and that additional methods need to be investigated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486938      PMCID: PMC2188130          DOI: 10.1084/jem.163.6.1539

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  39 in total

1.  Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

Authors:  D P Dialynas; Z S Quan; K A Wall; A Pierres; J Quintáns; M R Loken; M Pierres; F W Fitch
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

2.  Therapeutic potential of monovalent monoclonal antibodies.

Authors:  S P Cobbold; H Waldmann
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

3.  Univalent antibodies kill tumour cells in vitro and in vivo.

Authors:  M J Glennie; G T Stevenson
Journal:  Nature       Date:  1982-02-25       Impact factor: 49.962

4.  Preparation of monoclonal antibodies: strategies and procedures.

Authors:  G Galfrè; C Milstein
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

Review 5.  Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity.

Authors:  D P Dialynas; D B Wilde; P Marrack; A Pierres; K A Wall; W Havran; G Otten; M R Loken; M Pierres; J Kappler
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

6.  Effects of in vivo administration of monoclonal antibodies specific for human T cell subpopulations on the immune system in a rhesus monkey model.

Authors:  M Jonker; G Goldstein; H Balner
Journal:  Transplantation       Date:  1983-06       Impact factor: 4.939

7.  Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.

Authors:  D G Gilliland; Z Steplewski; R J Collier; K F Mitchell; T H Chang; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

Review 8.  Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma.

Authors:  J Ritz; S F Schlossman
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

9.  Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases.

Authors:  T W Smith; V P Butler; E Haber; H Fozzard; F I Marcus; W F Bremner; I C Schulman; A Phillips
Journal:  N Engl J Med       Date:  1982-11-25       Impact factor: 91.245

10.  Fine specificity of regulatory T cells. II. Suppressor and helper T cells are induced by different regions of hen egg-white lysozyme in a genetically nonresponder mouse strain.

Authors:  L Adorini; M A Harvey; A Miller; E E Sercarz
Journal:  J Exp Med       Date:  1979-08-01       Impact factor: 14.307

View more
  19 in total

1.  Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning.

Authors:  Luis Graca; Stephen Daley; Paul J Fairchild; Stephen P Cobbold; Herman Waldmann
Journal:  BMC Immunol       Date:  2006-04-25       Impact factor: 3.615

2.  CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo.

Authors:  Z Wang; J D Davies
Journal:  Int Immunopharmacol       Date:  2006-11-28       Impact factor: 4.932

Review 3.  Immunogenicity of biologic agents in rheumatology.

Authors:  Vibeke Strand; Joao Goncalves; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2020-12-14       Impact factor: 20.543

Review 4.  Therapeutic strategies with monoclonal antibodies and immunoconjugates.

Authors:  V S Byers; R W Baldwin
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

Review 5.  T cell tolerance induced by therapeutic antibodies.

Authors:  Stephen P Cobbold
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

6.  Treatment of encephalomyocarditis virus-induced central nervous system demyelination with monoclonal anti-T-cell antibodies.

Authors:  S Sriram; D J Topham; S K Huang; M Rodriguez
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

7.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Authors:  B K Finck; B Chan; D Wofsy
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

8.  Vectors for the expression of PCR-amplified immunoglobulin variable domains with human constant regions.

Authors:  M A Walls; K C Hsiao; L J Harris
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

9.  Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.

Authors:  Juan C Varela; Masaki Imai; Carl Atkinson; Rieko Ohta; Michelle Rapisardo; Stephen Tomlinson
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

10.  Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.

Authors:  J D Isaacs; N Burrows; M Wing; M T Keogan; P R Rebello; R A Watts; R J Pye; P Norris; B L Hazelman; G Hale; H Waldmann
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.